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Neoadjuvant chemotherapy has become the standard of care for locally advanced primary breast cancer.
Anthracycline-based regimens have proven to be one of the most effective treatments in this setting. As certain
cytotoxic antineoplastic agents, such as anthracyclines, generate reactive oxygen species as a by-product of
their mechanism of action, we examined whether redox protein expression was involved in the response to
anthracycline-based chemotherapy and with clinical outcome. Pre-treatment needle core biopsy and post-
anthracycline treatment tumour sections were analysed from 98 cases. In all, 32 individuals had a complete
clinical response and 17 had a complete pathological response. Immunohistochemical staining was performed
for eight redox proteins: thioredoxin, thioredoxin reductase, thioredoxin interacting protein (TxNIP), glutathione
S-transferase (GST) p, h and a, catalase and manganese superoxide dismutase. GST p (P¼ 0.05) and catalase
(P¼ 0.045) were associated with pathological complete response in pre-chemotherapy samples. TxNIP
(P¼ 0.017) and thioredoxin reductase (P¼ 0.022) were independent prognostic factors for distant metastasis-
free survival and TxNIP for overall survival (P¼ 0.014). In oestrogen receptor negative patients that are known to
have a poor overall survival, a considerably worse prognosis was seen in cases that exhibited low expression of
TxNIP (P¼ 0.000003), stratifying patients into more defined groups. This study indicates the importance of
redox regulation in determining breast cancer response to anthracycline-based chemotherapy and provides
ways of further stratifying pre-chemotherapy patients to potentially allow more tailored treatments.
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Neoadjuvant chemotherapy has become the stan-
dard of care for locally advanced primary breast
cancer patients and aims to reduce tumour burden,
to render tumours operable, or facilitate breast
conservation and other oncoplastic options. In this
setting, anthracycline-based regimens are commonly
used. Anthracyclines have a complex mechanism of
action including inhibition of enzymes such as
topoisomerase II, resulting in DNA double-strand
breaks, intercalation into DNA and also generation
of reactive oxygen species.1 The anthracycline drugs
have a quinone that undergoes reduction to a semi-
quinone-free radical, forming superoxide anions in
the presence of oxygen. After dismutation, resultant
hydrogen peroxide (H2O2) can be converted into
the highly damaging hydroxyl radical.2 The semi-
quinone radical can also intercalate and damage
DNA. There are currently no markers to determine
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response to neoadjuvant chemotherapy in locally
advanced primary breast cancer.
In cancer, the normal redox balance is disrupted
due to increased oxidative stress caused by accele-
rated cell proliferation, constant stimulation of
growth promoting signalling pathways and altera-
tions in metabolic activity. Due to this, redox
buffering systems such as the thioredoxin and
glutathione systems, and antioxidant enzymes such
as catalase and superoxide dismutase are often
deregulated/overexpressed to compensate.3–6 These
processes can add to the oncogenic transformation
and mutation rate in tumours and influence their
response to reactive oxygen species generating
therapies.7,8
The current study investigates expression of a
panel of redox proteins representing the key path-
ways: thioredoxin, thioredoxin reductase, thio-
redoxin interacting protein (TxNIP), glutathione
S-transferase (GST) p, y, a, catalase and manganese
superoxide dismutase (MnSOD), in a well-defined
cohort of pre-treatment locally advanced primary
breast cancer patients before anthracycline chemo-
therapy. Their expression was investigated for
response to therapy and aiding prognosis. A post-
chemotherapy tumour specimen was available from
certain patients that allowed a matched compa-
rison of protein expression to be assessed, yielding
information on particular redox pathways that are
altered in response to chemotherapy.
Materials and methods
Clinical Samples
The study is reported according to REMARK
criteria.9 The consecutive cohort consisted of
98 patients presenting with locally advanced pri-
mary breast cancer between December 1996 and
December 2009 at Nottingham University Hospitals
and treated with neoadjuvant anthracycline-based
chemotherapy. The core biopsies from 82 patients
were assessed for all redox proteins studied, 16
additional patients were available for assessment of
TxNIP only (n¼ 98). A core biopsy was performed
before chemotherapy to allow pathological diagno-
sis and evaluation of biological parameters. Patients
were then treated with six cycles of anthracycline-
based therapy (5-fluorouracil (5-FU) 500mg/m2,
epirubicin 75–100mg/m2, cyclophosphamide
500mg/m2, on day 1 of a 21-day cycle). Patients
underwent surgery 4 weeks after the sixth cycle,
unless progression after three cycles, in which case
taxanes were used. All oestrogen receptor positive
cases received adjuvant hormonal treatment.
Assessment of tumour response was undertaken
before chemotherapy and after each cycle. The
clinical baseline and preoperative measurements
were obtained with a calliper by the same clini-
cian or by radiological assessment. Clinical res-
ponse was recorded according to RECIST criteria.10
The pathological response was evaluated by histo-
logical examination of tumour removed following
chemotherapy. For certain cases, whole tumour
sections post-chemotherapy were available for redox
protein assessment as matched pairs to the pre-
chemotherapy samples (see Results section for num-
bers). Histology was reviewed using the Chevallier
classification.11 Ethical approval was obtained from
the Nottingham Research Ethics Committee (C202313).
Immunohistochemistry
Immunohistochemistry was performed on core
biopsies and whole tumour sections as previously
described.5 Briefly, microwave antigen retrieval
was conducted in 0.01mol/l sodium citrate buffer
(pH 6). Primary antibodies were incubated for
60min at room temperature (thioredoxin 1:1000
(#705, American Diagnostica, Stamford, USA),
thioredoxin reductase 1:1000 (#07-613, Millipore,
Billerica, USA), TxNIP 1:3000 (clone JY2, MBL
International Corporation, Woburn, USA), catalase
1:5000 (#ab1877, Abcam, Cambridge, UK), MnSOD
1:1000 (#ab13533, Abcam), GST a (clone 2F7) 1:333,
GST y (clone 2E10-1B2) 1:500 (Abnova, Taipei City,
Taiwan), GST p 1:2000 (#MSA-102, Assay Designs,
Michigan, USA)). Blocking, secondary, ABC and
3,30-diaminobenzidine (DAB) substrate reagents
were supplied in kit form from Vector Labs (Vector
Laboratories, Burlingame, USA). Primary antibody
was omitted for negative controls. Placenta and
breast composite blocks (six stage I breast carcino-
mas, including grade I–III tumours) were used for
antibody optimisations and positive controls, with
liver sections used for GST a. All antibodies had
been previously assessed for specificity using
western blotting on a panel of breast cancer cell
lysates.
Assessment of protein staining was conducted by
standard semiquantitative immunohistochemistry
scoring (H score) conducted independently by
two assessors blinded to the study end points.
Staining intensity was divided into: none (0), weak
(1) moderate (2) and strong (3). H scores were
calculated by multiplying the percentage of positive
tumour by the staining intensity (range 0–300). Low-
vs high-expressing tumours were determined using
median H scores—thioredoxin 190, thioredoxin
reductase 200, TxNIP 160, GST y 185, GST p 85,
catalase 90, MnSOD 175. No tumour staining was
observed for GST a.
Statistical Analysis
SPSS version 15.0 software package was used for
statistical analysis. Protein expression vs clinico-
pathological criteria was assessed using the Pearson
w2 test of association or Fisher’s exact test when
there are less than five cases in a cell. Survival
analysis was conducted using Kaplan–Meier and
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Table 1 Clinicopathological criteria of locally advanced primary breast cancer patients who underwent neoadjuvant anthracycline-based chemotherapy
Thioredoxin Thioredoxin
reductase
TxNIP Glutathione
S-transferase p
Glutathione
S-transferase y
Catalase Manganese
superoxide
Low
(%)
High
(%)
P-value Low
(%)
High
(%)
P-value Low
(%)
High
(%)
P-value Low
(%)
High
(%)
P-value Low
(%)
High
(%)
P-value Low
(%)
High
(%)
P-value Low
(%)
High
(%)
P-value
Age (years)
r40 10 (71) 4 (29) 0.217 7 (47) 8 (53) 0.393 6 (38) 10 (62) 0.352 7 (54) 6 (46) 0.747 8 (67) 4 (33) 0.284 9 (60) 6 (40) 0.790 7 (47) 8 (53) 0.840
41–60 20 (47) 23 (53) 24 (56) 19 (44) 33 (58) 24 (42) 19 (46) 22 (54) 17 (43) 23 (57) 20 (50) 20 (50) 22 (54) 19 (46)
460 6 (43) 8 (57) 10 (71) 4 (29) 9 (53) 8 (47) 8 (57) 6 (43) 8 (57) 6 (43) 7 (50) 7 (50) 6 (46) 7 (54)
Total 36 35 41 31 48 42 34 34 33 33 36 33 35 34
Histology
Ductal NST 35 (53) 31 (47) 0.170* 38 (57) 29 (43) 0.632* 43 (52) 40 (48) 0.276* 33 (52) 30 (48) 0.178* 30 (48) 32 (52) 0.307* 34 (53) 30 (47) 0.458* 33 (52) 31 (48) 0.486*
Lobular 1 (20) 4 (80) 3 (60) 2 (40) 5 (71) 2 (29) 1 (20) 4 (80) 3 (75) 1 (25) 2 (40) 3 (60) 2 (40) 3 (60)
Total 36 35 41 31 34 34 33 33 36 33 35 34
TNM stage
2 4 (50) 4 (50) 0.593* 3 (33) 6 (67) 0.135* 6 (40) 9 (60) 0.293 5 (63) 3 (37) 0.337* 3 (43) 4 (57) 0.537* 5 (63) 3 (37) 0.408* 5 (63) 3 (37) 0.372*
3 31 (53) 28 (47) 35 (59) 24 (41) 39 (55) 32 (45) 27 (47) 30 (53) 27 (49) 28 (51) 29 (51) 28 (49) 28 (49) 29 (51)
Total 35 32 38 30 45 41 32 33 30 32 34 31 33 32
ER status
Negative 18 (49) 19 (51) 0.718 20 (53) 18 (47) 0.435 23 (52) 21 (48) 0.844 16 (46) 19 (54) 0.467 15 (43) 20 (57) 0.218 21 (60) 14 (40) 0.187 15 (43) 20 (57) 0.185
Positive 18 (53) 16 (47) 21 (62) 13 (38) 25 (54) 21 (46) 18 (55) 15 (45) 18 (58) 13 (42) 15 (44) 19 (66) 20 (59) 14 (41)
Total 36 35 41 31 48 42 34 34 33 33 36 33 35 34
PgR status
Negative 20 (54) 17 (46) 0.329 21 (55) 17 (45) 0.464 25 (56) 20 (44) 0.066 17 (49) 18 (51) 0.916 16 (47) 18 (53) 0.316 25 (69) 11 (31) 0.198 18 (50) 18 (50) 0.862
Positive 9 (41) 13 (59) 10 (45) 12 (55) 11 (34) 21 (66) 11 (50) 11 (50) 7 (33) 14 (67) 11 (52) 10 (48) 11 (52) 10 (48)
Total 29 30 31 29 36 41 28 29 23 32 36 21 29 28
HER status
Negative 17 (43) 23 (57) 0.458 20 (48) 22 (52) 0.174 29 (52) 27 (48) 0.635 18 (45) 22 (55) 0.107 15 (38) 24 (62) 0.116 24 (60) 16 (40) 0.677 21 (54) 18 (46) 0.647
Positive 12 (52) 11 (48) 15 (65) 8 (35) 12 (46) 14 (54) 14 (67) 7 (33) 12 (60) 8 (40) 12 (55) 10 (45) 11 (48) 12 (52)
Total 29 34 35 30 41 41 32 29 27 32 36 26 32 30
Pathological complete response
CR 7 (54) 6 (46) 0.802 7 (50) 7 (50) 0.559 7 (44) 9 (56) 0.397 3 (25) 9 (75) 0.050* 6 (46) 7 (54) 0.757 10 (77) 3 (23) 0.045* 8 (62) 5 (38) 0.387
Non-CR 29 (50) 29 (50) 34 (59) 24 (41) 41 (55) 33 (45) 31 (55) 25 (45) 27 (51) 26 (49) 26 (46) 30 (54) 27 (48) 29 (52)
Total 36 35 41 31 48 42 34 34 33 33 36 33 35 34
Clinical complete response
CR 15 (56) 12 (44) 0.522 14 (50) 14 (50) 0.342 13 (43) 17 (57) 0.202 16 (64) 9 (36) 0.078 15 (60) 10 (40) 0.205 16 (59) 11 (41) 0.345 16 (59) 11 (41) 0.256
Non-CR 21 (48) 23 (52) 27 (61) 17 (39) 34 (58) 25 (42) 18 (42) 25 (58) 18 (44) 23 (56) 20 (48) 22 (52) 19 (45) 23 (55)
Total 36 35 41 31 47 42 34 34 33 33 36 33 35 34
Pearson’s w2 test of association values stated unless the frequency of observations in a cell was o5; therefore, Fisher’s exact stated (indicated by *).
Statistically significant P-values are indicated by bold font.
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significance was determined using log rank. Cox
proportional hazards model was used to test statis-
tical independence and paired t-test for the relation-
ship between pre- and post-tumour expression
levels. Intraclass correlations were applied to deter-
mine the consistency, or conformity, between asses-
sors using the continuous scores that were produced
by each individual scoring independently from the
same tissue sections. All differences were deemed
statistically significant at the level of Po0.05.
Results
Redox Proteins Expression and Clinicopathological
Characteristics
Table 1 shows the full clinicopathologic character-
istics of the patient cohort that were assessable for
each protein. In B80% of cases, the maximum risk
of recurrence was within the first 2 years. Only 15
living cases (15%) had a follow-up time r2 years.
The median age of patients was 51 with a range of
25–76 years. The assessment of protein expression
was conducted with a high level of concordance
between independent observers: thioredoxin 0.962,
thioredoxin reductase 0.976, TxNIP 0.838, GST y
0.930, GST p 0.973, catalase 0.964, MnSOD 0.916.
All proteins were assessed for cytoplasmic staining,
with some granularity and heterogeneity between
adjacent tumour cells, varying from weak to intense
staining. Some occasional nuclear staining was
observed for thioredoxin, thioredoxin reductase
and GST p but was not assessed. Figures 1 and 2
demonstrate the immunostaining pattern of the
proteins. No expression of GST awas observed apart
from in the liver sections that were used as positive
Figure 1 Photomicrographs of low (left panel) and high (right panel) immunohistochemical protein expression at 10 magnification (a)
thioredoxin (b) thioredoxin reductase (c) thioredoxin interacting protein (d) manganese superoxide dismutase. Stain is 3,30-
diaminobenzidine counterstained with haematoxylin.
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controls (Figure 2d). The expression of redox
proteins in the pre-chemotherapy samples was not
associated with clinicopathologic characteristics,
that is, TNM stage, histopathologic subtype, oestro-
gen receptor, HER2, progesterone receptor status or
age (Table 1).
Redox Protein Expression and Response
Pathological complete response is the most reliable
end point of response to neoadjuvant treatment.
For this study, pathological complete response was
analysed vs partial response, stable disease and
progressed disease that were grouped due to the
limited numbers in certain categories. Borderline
associations were observed for GST p (w2¼ 3.643,
df¼ 1, P¼ 0.05) and catalase (w2¼ 3.932, df¼ 1,
P¼ 0.045) with pathological complete response in
the pre-chemotherapy biopsy samples. From the
cases that had completely responded, 75% (9/12)
had high GST p levels and 77% (10/13) a low
expression of catalase. Thioredoxin P¼ 0.802, thio-
redoxin reductase P¼ 0.559, TxNIP P¼ 0.397, GST y
P¼ 0.757 and MnSOD P¼ 0.387 showed no associa-
tion with pathological complete response (Table 1).
Oestrogen receptor negative tumours are known to
achieve a better pathological complete response12,13
and in this cohort, oestrogen receptor status was
significantly associated with pathological complete
response (w2¼ 7.572, df¼ 1, P¼ 0.005) with 82%
(14/17) of responders being oestrogen receptor
negative. Therefore, the combination of GST p or
catalase expression with oestrogen receptor status was
assessed in the pre-chemotherapy biopsies vs patho-
logical complete response. Data were grouped into
four combinations, that is, oestrogen receptor negative
with low redox protein expression, oestrogen receptor
negative with high redox protein expression, oestrogen
receptor positive with low redox protein expression
Figure 1 Continued.
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and oestrogen receptor positive with high redox
protein expression. In all, 67% (8/12) of complete res-
ponders had a high expression of GST p in oestrogen
receptor negative tumours (w2¼ 11.024, df¼ 3, P¼
0.012). Analysing this category (ie, oestrogen receptor
negative/GST p high) against the other subgroups
combined highlighted a strong significant association
with pathological complete response (w2¼ 10.853,
df¼ 1, P¼ 0.002). Catalase/oestrogen receptor combi-
nations showed that the association of a low expres-
sion of catalase with oestrogen receptor negative was
of interest in the complete responders (w2¼ 4.147,
df¼ 1, P¼ 0.042, 53.8% cases (7/13)).
Redox protein expression was not associated with
clinical complete response—TxNIP P¼ 0.202, thio-
redoxin P¼ 0.522, thioredoxin reductase P¼ 0.342,
GST y P¼ 0.205, GST p P¼ 0.078, catalase P¼ 0.345,
MnSOD P¼ 0.256 (Table 1). Clinical complete
response was also analysed as complete response
vs partial response, stable disease and progressed
disease grouped.
Redox Protein Expression and Survival
The age of the patients (r40, 40–60, 460) was
significantly associated with distant metastasis-free
survival (P¼ 0.032) with ther40 age group showing
good prognosis. Ther40 group also showed a signi-
ficantly better overall survival (P¼ 0.04). However,
it should be noted that this cohort is a relatively
small and homogeneous population.
In the pre-chemotherapy biopsies, Figure 3a
demonstrates that a high expression of TxNIP
Figure 2 Photomicrographs of low (left panel) and high (right panel) immunohistochemical protein expression at 10 magnification (a)
glutathione S-transferase y (b) glutathione S-transferase p (c) catalase. Positive control showing glutathione S-transferase a staining on
liver sections (d) and (e) breast composite demonstrating absence of staining. Stain is 3,30-diaminobenzidine counterstained with
haematoxylin.
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(P¼ 0.021) and Figure 3b demonstrates that a high
expression of thioredoxin reductase (P¼ 0.021), was
associated with distant metastasis-free survival.
Multivariate analysis (Table 2) shows that TxNIP
(P¼ 0.017, hazard ratio (HR)¼ 0.3, 95% confidence
interval (CI)¼ 0.1–0.8) and thioredoxin reductase
(P¼ 0.022, HR¼ 0.3, 95% CI¼ 0.1–0.8) are indepen-
dent factors. Distant metastasis-free survival showed
no association with hormone receptor status using
Kaplan–Meier/log rank analysis (oestrogen receptor
P¼ 0.180, HER2 P¼ 0.585, progesterone receptor
P¼ 0.892) and is not known to be of prognostic
value in this setting; therefore, no further statistical
analysis was conducted incorporating redox protein
expression.
In the pre-chemotherapy biopsies, Figure 4a
shows that a high expression of TxNIP was asso-
ciated with a better overall survival (P¼ 0.037).
Multivariate analysis demonstrated that TxNIP is an
independent prognostic factor (P¼ 0.014, HR¼ 0.2,
95% CI¼ 0.1–0.7) and, of note, independent of
oestrogen receptor status (P¼ 0.001, HR¼ 0.1, 95%
CI¼ 0.0–0.3) (Table 2).
Despite the better pathological complete response
from oestrogen receptor negative tumours, surpris-
ingly oestrogen receptor negative patients are known
to have a worse overall survival,12,13 which was also
observed in this cohort (P¼ 0.014) (Figure 4b).
Therefore, TxNIP expression with oestrogen receptor
status was analysed, using the same combinations
as for pathological complete response. Oestrogen
receptor negative/low TxNIP expression had a con-
siderably worse prognosis (P¼ 0.00006) (Figure 4c).
Analysing this group against the remaining groups
combined was highly significant (P¼ 0.000003)
(Figure 4d) and was an independent prognostic
factor (P¼ 0.0003, HR¼ 0.1, 95% CI¼ 0.0–0.4)
(Table 2). Oestrogen receptor negative patients can
therefore be notably stratified further using TxNIP
expression.
Figure 2 Continued.
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Comparison of Redox Expression Pre- and
Post-Anthracycline-Based Chemotherapy
A paired set of tumour samples, pre- and post-
chemotherapy, were available for certain patients
and therefore changes in redox protein expres-
sion were evaluated. Thioredoxin (n¼ 41), TxNIP
(n¼ 39), GST y (n¼ 43) and MnSOD (n¼ 20) all
showed significant increases in expression
levels after anthracycline-based chemotherapy
(P¼ 0.00000002, P¼ 0.006, P¼ 0.023 and P¼ 0.048,
respectively) (Figure 5). Although results point
towards these pathways being activated by chemo-
therapy, the level of increase of these four redox
proteins was not significant against clinical para-
meters such as pathological complete response,
distant metastasis-free or overall survival. This was
not unexpected due to the small sample size
involved but this would warrant further investiga-
tion in a larger cohort and in serial biopsies after
each chemotherapy cycle. Thioredoxin reductase
(n¼ 31), GST p (n¼ 46) and catalase (n¼ 22) showed
no significant change (P¼ 0.762, P¼ 0.274 and
P¼ 0.214, respectively).
Discussion
To our knowledge, this is the first study to examine
a panel of redox proteins in a well-defined cohort
of locally advanced primary breast cancer cases
before receiving neoadjuvant anthracycline-based
chemotherapy. Limited studies have utilised pre-
biopsy samples and the numbers are generally small
due to the nature of the sample type. Results demon-
strate that the expression of redox proteins in initial,
pre-treatment, tumour specimens may be important
prognostically and as determinants of response.
The observed absence of expression of GST a was
mirrored in two previous studies that reported very
low expression in both normal and breast tumour
tissues14 and decreased immunointensity in tumour
compared with normal.15
High GST p expression associated with a greater
probability of pathological complete response and
notably further stratified oestrogen receptor negative
patients (P¼ 0.002). GST p expression has been
linked to oestrogen receptor status and also showed
an inverse correlation,16–18 but this is the first report
in pre-chemotherapy locally advanced primary
breast cancer. Due to the nature of GST p as a
detoxification enzyme, studies have connected its
high expression to multidrug resistance in various
cancers19,20 but although the literature related to
GST p, anthracyclines and breast cancer is relatively
consistent in vitro, the in vivo data are contradictory.
In certain studies, a high GST p expression was
associated with a shorter distant metastasis-free and
overall survival21,22 whereas others had a better
outcome.23,24 The current study saw no significance
with distant metastasis-free or overall survival. In
contrast, a low expression of catalase was associated
with a greater incidence of pathological complete
response (P¼ 0.045). Catalase functions to catalyse
the decomposition of H2O2 to water and oxygen.
When catalase expression is low, H2O2 formed by
anthracyclines may be less effectively processed
resulting in hydroxyl radicals and potentially
tumour cell death, thus pathological complete
response.
High expression of thioredoxin reductase was a
prognostic factor for better distant metastasis-free
survival (P¼ 0.022). Such results may appear to
contradict the systems antioxidant function, but it
has been shown that endogenous thioredoxin
increases the redox cycling of anthracyclines and
enhances their apoptotic potential.25 An increased
Figure 3 Kaplan–Meier distant metastasis-free survival curves.
High thioredoxin interacting protein (a) and high thioredoxin
reductase (b) correlate with a good prognosis (P¼0.021,
P¼0.021).
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Table 2 Multivariate Cox proportional hazards analysis for predictors of distant metastasis-free and overall survival in locally advanced
primary breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy
Multivariate analysis for distant metastasis-free survival
TxNIP Thioredoxin reductase
Hazard ratio 95% CI Significance Hazard ratio 95% CI Significance
Protein 0.3 0.1–0.8 0.017* 0.3 0.1–0.8 0.022*
ER 0.1 0.0–0.5 0.002* 0.2 0.1–0.7 0.011*
HER2 1.5 0.6–4.2 0.424 1.7 0.6–5.2 0.327
PgR 3.5 1.1–11.7 0.038* 2.1 0.7–6.1 0.166
TNM 1.2 0.3–5.4 0.837 1.7 0.2–14.6 0.642
Age 2.9 1.1–7.3 0.027* 1.8 0.7–4.2 0.206
Multivariate analysis for overall survival
TxNIP TxNIP with ER status
Hazard ratio 95% CI Significance Hazard ratio 95% CI Significance
Protein 0.2 0.1–0.7 0.014* 0.1 0.0–0.4 0.0003*
ER 0.1 0.0–0.3 0.001* — — —
HER2 0.4 0.1–2.1 0.294 1.1 0.4–2.8 0.920
PgR 2.1 0.5–8.5 0.288 2.3 0.8–6.7 0.139
TNM 0.4 0.1–2.0 0.254 1.6 0.4–7.1 0.553
Age 3.0 1.1–8.3 0.035* 2.6 1.1–6.2 0.029*
Abbreviation: CI, confidence interval.
*Statistically significant.
Figure 4 Kaplan–Meier overall survival curves. (a) A high expression of thioredoxin interacting protein is significantly associated with a
better prognosis (P¼0.037). (b) Oestrogen receptor status is an independent predictive factor (P¼0.014 in this cohort). Therefore,
correlations were made between redox proteins and oestrogen receptor status by grouping patients: 1¼oestrogen receptor negative with
low redox expression, 2¼ oestrogen receptor negative with high redox expression, 3¼oestrogen receptor positive with low redox
expression, 4¼oestrogen receptor positive with high redox expression. (c) Oestrogen receptor negative cases with a low thioredoxin
interacting protein expression had a considerably worse prognosis (P¼0.00006) (group 1) and analysing this group against the others
combined (d) was highly significant (P¼0.000003).
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expression of thioredoxin reductase would maintain
thioredoxin in its reduced, active state.
In the present study, high expression of TxNIP
was also a prognostic factor for a better distant
metastasis-free (P¼ 0.017) and overall survival
(P¼ 0.014). Strikingly though, TxNIP combined
with oestrogen receptor status subdivided the
oestrogen receptor negative cases into those with
comparable prognosis to oestrogen receptor positive
and those that had a poor outcome for overall
survival (P¼ 0.000003). To our knowledge, this is
the first study to examine the relationship between
TxNIP in neoadjuvant locally advanced primary
breast cancer cases. One study assessed RNA
expression in breast cancer patients that had no
treatment and found that a high level of TxNIP was
significant for a better metastasis-free survival.26
TxNIP is a competitive inhibitor of thioredoxin.
Overexpression of TxNIP inhibits proliferation of
tumour cells,27 environmental conditions such as
H2O2 can upregulate its expression
28 and it is
downregulated in a number of cancers.27,29 TxNIP
can also function through alternative mechanisms
such as Jun activating binding protein affecting its
influence on p27kip1 [ref. 30] or via suppression of
cell invasion/metastasis by association with the
b domain of von Hippel-Lindau protein.31 Impor-
tantly, both TxNIP and thioredoxin reductase were
independent of oestrogen receptor. Despite reports
of oestrogens altering expression of certain redox
proteins,32,33 the authors have not found any reports
of this occurring for TxNIP or thioredoxin reductase.
In summary, redox protein expression can deter-
mine response to therapy and survival outcomes in
patients with locally advanced primary breast
cancer subsequently treated with neoadjuvant
chemotherapy. The high level of concordance
between individual assessors suggests that assess-
ment of redox protein expression may have clinical
potential.
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